Gilead and Kite present data across multiple difficult-to-treat cancers at ESMO

Gilead Sciences (GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology or ESMO Congress 2023. New clinical data for Trodelvy, sacituzumab govitecan-hziy, continue to support its use in metastatic triple-negative breast cancer or mTNBC and pre-treated HR+/HER2- metastatic breast cancer, mBC, and demonstrate the expanding body of evidence for Trodelvy in small cell lung cancer and head and neck cancer. Kite will also present analyses supporting the use of Yescarta axicabtagene ciloleucel in relapsed/refractory large B-Cell lymphoma LBCL. “Our data at ESMO 2023 reflect a broad clinical development program in difficult-to-treat cancers,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology. “Trodelvy has the potential to impact many patients with cancer across multiple indications, as demonstrated by presentations featuring new data in extensive-stage small cell lung cancer, metastatic urothelial cancer and previously treated head and neck cancer, along with new analyses in metastatic breast cancer.”